(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 June 2015 (11.06.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/084992 A1

(51) International Patent Classification:
A61K 31/5377 (2006.01) *A61P 35/00* (2006.01)
A61P 35/02 (2006.01)

(21) International Application Number:
PCT/US2014/068423

(22) International Filing Date:
3 December 2014 (03.12.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/911,978 4 December 2013 (04.12.2013) US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: **DI PAOLO, Julie**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **HAWKINS, Michael, J.**; 550 Davis Street #14, San Francisco, CA 94111 (US). **HU, Jing**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **JIN, Feng**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **MELCHOR-KHAN, Flordeliza**; 860 Moana Court, Palo Alto, CA 94306 (US). **REDDY, Anita**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(74) Agents: **ECK, Steven, R.** et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

[Continued on next page]

(54) Title: METHODS FOR TREATING CANCERS



(I)

(57) Abstract: Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma.

WO 2015/084992 A1

Published:

— *with international search report (Art. 21(3))*